Praxis Precision Medicines (PRAX) Competitors $73.68 +0.93 (+1.28%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRAX vs. TVTX, ICPT, LGND, CMPS, SAGE, RNA, CRNX, KRYS, ADMA, and TGTXShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Travere Therapeutics (TVTX), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), COMPASS Pathways (CMPS), Sage Therapeutics (SAGE), Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX), Krystal Biotech (KRYS), ADMA Biologics (ADMA), and TG Therapeutics (TGTX). These companies are all part of the "medical" sector. Praxis Precision Medicines vs. Travere Therapeutics Intercept Pharmaceuticals Ligand Pharmaceuticals COMPASS Pathways Sage Therapeutics Avidity Biosciences Crinetics Pharmaceuticals Krystal Biotech ADMA Biologics TG Therapeutics Travere Therapeutics (NASDAQ:TVTX) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Does the MarketBeat Community believe in TVTX or PRAX? Travere Therapeutics received 36 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. However, 71.93% of users gave Praxis Precision Medicines an outperform vote while only 57.04% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes7757.04% Underperform Votes5842.96% Praxis Precision MedicinesOutperform Votes4171.93% Underperform Votes1628.07% Which has preferable valuation and earnings, TVTX or PRAX? Travere Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$145.24M9.60-$111.40M-$4.55-3.93Praxis Precision Medicines$2.45M560.57-$123.28M-$10.30-7.15 Is TVTX or PRAX more profitable? Travere Therapeutics has a net margin of -172.75% compared to Praxis Precision Medicines' net margin of -9,409.22%. Praxis Precision Medicines' return on equity of -54.86% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-172.75% -537.74% -55.65% Praxis Precision Medicines -9,409.22%-54.86%-50.52% Do institutionals & insiders have more ownership in TVTX or PRAX? 67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.8% of Travere Therapeutics shares are held by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer TVTX or PRAX? In the previous week, Praxis Precision Medicines had 4 more articles in the media than Travere Therapeutics. MarketBeat recorded 10 mentions for Praxis Precision Medicines and 6 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.63 beat Praxis Precision Medicines' score of 0.32 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, TVTX or PRAX? Travere Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.67, meaning that its share price is 167% more volatile than the S&P 500. Do analysts rate TVTX or PRAX? Travere Therapeutics presently has a consensus target price of $22.62, indicating a potential upside of 26.63%. Praxis Precision Medicines has a consensus target price of $146.33, indicating a potential upside of 98.61%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85Praxis Precision Medicines 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 SummaryTravere Therapeutics and Praxis Precision Medicines tied by winning 9 of the 18 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.36B$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-7.154.8587.8613.46Price / Sales560.57374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book3.5910.216.946.30Net Income-$123.28M$153.61M$119.12M$225.93M7 Day Performance-4.16%-2.00%-1.84%-1.32%1 Month Performance0.75%-7.47%-3.65%0.60%1 Year Performance359.07%31.80%31.64%26.23% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines1.7647 of 5 stars$73.68+1.3%$146.33+98.6%+299.3%$1.36B$2.45M-7.15110TVTXTravere Therapeutics3.0581 of 5 stars$17.86+2.7%$22.62+26.6%+210.6%$1.36B$145.24M0.00460ICPTIntercept PharmaceuticalsN/A$19.00flatN/AN/A$794.77M$285.71M-12.84341LGNDLigand Pharmaceuticals4.9545 of 5 stars$111.56-0.2%$144.83+29.8%+91.9%$2.11B$131.31M44.4580CMPSCOMPASS Pathways2.8558 of 5 stars$4.66-2.1%$30.67+558.1%-23.0%$318.84MN/A0.00120Short Interest ↓SAGESage Therapeutics4.2697 of 5 stars$4.91flat$12.89+162.5%-75.1%$300.36M$86.46M-0.88690Analyst ForecastNews CoverageGap DownRNAAvidity Biosciences2.3883 of 5 stars$43.65+0.9%$63.22+44.8%+631.2%$5.16B$9.56M0.00190Insider TradeAnalyst RevisionCRNXCrinetics Pharmaceuticals3.5524 of 5 stars$56.07+1.6%$70.18+25.2%+85.5%$5.12B$4.01M0.00210Analyst RevisionKRYSKrystal Biotech4.8348 of 5 stars$178.10+0.1%$202.29+13.6%+70.0%$5.12B$50.70M100.62229Positive NewsADMAADMA Biologics3.3177 of 5 stars$21.51+0.7%$21.25-1.2%+430.3%$5.08B$258.21M76.32530TGTXTG Therapeutics4.2178 of 5 stars$31.15+2.7%$37.67+20.9%+143.0%$4.85B$233.66M0.00290Positive News Related Companies and Tools Related Companies Travere Therapeutics Competitors Intercept Pharmaceuticals Competitors Ligand Pharmaceuticals Competitors COMPASS Pathways Competitors Sage Therapeutics Competitors Avidity Biosciences Competitors Crinetics Pharmaceuticals Competitors Krystal Biotech Competitors ADMA Biologics Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRAX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
